Ruxolitinib targets DCs: For better or worse?

Research output: Contribution to journalShort surveypeer-review

7 Scopus citations


In this issue of Blood, Heine et al demonstrate the dose-dependent inhibitory effect of ruxolitinib on the generation of dendritic cells (DCs) from monocytes. The drug also inhibited DC activation, tissue migration, and induction of allogeneic or antigen-specific T-cell responses, including in vivo viral clearance.

Original languageEnglish (US)
Pages (from-to)1096-1097
Number of pages2
Issue number7
StatePublished - Aug 15 2013

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Ruxolitinib targets DCs: For better or worse?'. Together they form a unique fingerprint.

Cite this